Nearly home.

Isn't home where we all want to be?

Reba here for Realtor.com, the pro's number one most trusted app.

A dream home isn't a dream home if it comes with a nightmare commute.

That's why realter.com has real commute, so you can search by drive time.

Download the realtor.com app today because you're nearly home. Make it real with

real with realtor.com. Pros number one most trusted app based on August 2025 proprietary survey.

Here's your midday brief for Monday, November 17th. I'm Zoe Colkin for the Wall Street Journal.

Novo Nordisk is cutting prices for its obesity drugs, making the first two monthly doses of Wagovi and OZempic

available for $199 a month for cash-paying customers between now and the end of March. After those first two months,

patients will pay the new standard cash monthly price of $349, down from a previous price of $499.

The Denmark-based company is implementing these price reductions ahead of an agreement with the Trump

administration,

which mandates it lowered GLP1 drug costs.

Johnson & Johnson has agreed to acquire HALDA therapeutics for just over $3 billion in cash,

bolstering the health care giant's oncology pipeline.

Johnson and Johnson said the deal, expected to close within the next few months, adds HALDA's proprietary platform for developing oral targeted therapies for

multiple types of solid tumors, including prostate cancer. Johnson & Johnson is expecting the HALDA acquisition

to reduce its 2026 adjusted per share earnings by about 15 cents

due to short-term financing and a charge related to equity awards for HALDA employees.

And Federal Reserve Governor Philip Jefferson said the Fet should proceed slowly with any

further interest rate cuts to avoid potentially undermining anti-inflation

...